The Roche Group is forecasting a decline in sales by a low single digit percentage at constant exchange rates this year due to a steep drop in sales for its Covid-19 diagnostic products. Excluding the Covid-19 effect, the company expects to show solid growth in the base business. Roche’s pharmaceuticals division continued to be the stronger player, generating three times the sales volume as that of diagnostics.
